Investigative Ophthalmology & Visual Science Cover Image for Volume 62, Issue 8
June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Longitudinal OCTA changes in non-proliferative diabetic retinopathy
Author Affiliations & Notes
  • Nita Valikodath
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • David Le
    Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, Chicago, Illinois, United States
  • Xiang Li
    Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, Chicago, Illinois, United States
  • Xincheng Yao
    Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, Chicago, Illinois, United States
  • Jennifer I Lim
    Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Nita Valikodath, None; David Le, None; Xiang Li, None; Xincheng Yao, None; Jennifer Lim, Adverum (F), Aldeyra Therapeutics (F), Allergan (C), Chengdu Kanghong (F), Clearside (F), Cognition (C), Eyenuk (C), Genentech (F), Genentech (C), Greybug (F), Iveric (C), Kodiak (C), Luxa (C), NGM (F), Novartis (C), Opthea (C), pSivida (C), Quark (C), Santen (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1087. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nita Valikodath, David Le, Xiang Li, Xincheng Yao, Jennifer I Lim; Longitudinal OCTA changes in non-proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1087.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate optical coherence tomography angiography (OCTA) changes in patients with non-proliferative diabetic retinopathy (NPDR)

Methods : This is a preliminary study to explore early vessel parameter changes after an anti-VEGF intravitreal injection in eyes with macular edema and NPDR. The electronic medical record was reviewed to obtain information regarding disease severity, presence of diabetic macular edema and treatment. OCTA information was reviewed and six quantitative OCTA features including VCI (vessel complexity index), VAD (vessel area density), VSD (vessel skeleton density), BVT (blood vessel tortuosity), VDI (vessel diameter index), and VPI (vessel perimeter index) were recorded. Statistical analyses were performed using MATLAB (Mathworks, Natick, MA, USA).

Results : A total of 23 eyes of 19 patients were evaluated across three visits. Mean visual acuity was 20/40 at visit 1, 20/50 at visit 2 and 20/50 at visit 3. From visit 1 to visit 2, 21 eyes remained stable, 3 eyes improved, and 6 eyes worsened in severity. From visit 2 to visit 3, 20 eyes remained stable, 7 eyes improved and 2 eyes worsened.

VCI was 0.37±0.23 at visit 1, 0.46±0.32 at visit 2, and 0.39±0.32 at visit 3 (visit 1 and 2, p=0.09). VAD was 0.43±0.27 at visit 1, 0.54±0.31 at visit 2, and 0.48±0.33 at visit 3 (visit 1 and 2, p=0.01). VSD was 0.45±0.28 at visit 1, 0.54±0.31 at visit 2, and 0.45±0.32 at visit 3 (visit 1 and 2, p=0.03 and visit 2 and visit 3, p=0.08). BVT was 0.56±0.22 at visit 1, 0.41±0.27 at visit 2 and 0.44±0.26 at visit 3 (visit 1 and 2, p=0.01 and visit 1 and visit 3, p=0.04). VDI was 0.25±0.33 at visit 1, 0.18±0.26 at visit 2, and 0.22±0.25 at visit 3 (visit 2 and 3, p=0.006). VPI was 0.58±0.29 at visit 1, 0.44±0.26 at visit 2, and 0.61±0.31 at visit 3 (visit 1 and 2, p< 0.001, visit 2 and 3, p=0.001). See Figure 1 for an example of a patient with NPDR and OCTA changes.

Conclusions : Quantitative OCTA features including VAD, VSD, VPI, and BVT changed significantly between visits and can detect early changes in NPDR.

This is a 2021 ARVO Annual Meeting abstract.

 

Right eye of patient from visit 1 (moderate NPDR), visit 2 (moderate NPDR), and visit 3 (mild NPDR). The patient was treated and showed regression from moderate to mild NPDR. The top row displays the enface OCTA and the bottom row displays the binarized vessel map.

Right eye of patient from visit 1 (moderate NPDR), visit 2 (moderate NPDR), and visit 3 (mild NPDR). The patient was treated and showed regression from moderate to mild NPDR. The top row displays the enface OCTA and the bottom row displays the binarized vessel map.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×